Instrument Inactif

Communiqués Novus Therapeutics, Inc. Nasdaq

Actions

Recherche biotechnologique et médicale

Communiqués

13/08	Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights	GL
21/07	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up	AQ
08/07	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy	AQ
22/06	Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus	GL
08/06	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine	GL
04/06	Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions	GL
20/05	Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress	GL
13/05	Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights	GL
07/05	Unspoken Perspectives: Patient Sentiments Toward Clinical Trials in Kidney Transplantation	PU
30/04	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026	AQ
19/03	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results	GL
16/03	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine	GL
16/03	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine	AQ
10/03	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation	GL
04/03	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference	GL
05/02	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	GL
26/01	American Society of Transplant Surgeons Winter Symposium, January 23, 2026: Long-Term Outcomes of a Phase 1, Single-Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen	PU
23/01	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium	GL
20/01	American Journal of Transplantation: December 24, 2025 Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model	PU
08/01	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook	GL
01/12	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference	GL
01/12	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference	AQ
18/11	Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine	GL
14/11	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results	GL
12/11	Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants	GL